Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?
Overview
Chemistry
Molecular Biology
Authors
Affiliations
Colorectal cancer (CRC) is a predominant malignancy worldwide, being the fourth most common cause of mortality and morbidity. The CRC incidence in adolescents, young adults, and adult populations is increasing every year. In the pathogenesis of CRC, various factors are involved including diet, sedentary life, smoking, excessive alcohol consumption, obesity, gut microbiota, diabetes, and genetic mutations. The CRC tumor microenvironment (TME) involves the complex cooperation between tumoral cells with stroma, immune, and endothelial cells. Cytokines and several growth factors (GFs) will sustain CRC cell proliferation, survival, motility, and invasion. Epidermal growth factor receptor (EGFR), Insulin-like growth factor -1 receptor (IGF-1R), and Vascular Endothelial Growth Factor -A (VEGF-A) are overexpressed in various human cancers including CRC. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) and all the three major subfamilies of the mitogen-activated protein kinase (MAPK) signaling pathways may be activated by GFs and will further play key roles in CRC development. The main aim of this review is to present the CRC incidence, risk factors, pathogenesis, and the impact of GFs during its development. Moreover, the article describes the relationship between EGF, IGF, VEGF, GFs inhibitors, PI3K/AKT/mTOR-MAPK signaling pathways, and CRC.
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer.
Haynes J, Manogaran P Int J Mol Sci. 2025; 26(5).
PMID: 40076613 PMC: 11901061. DOI: 10.3390/ijms26051988.
Investigating the PI3K/AKT/mTOR axis in Buzhong Yiqi Decoction's anti-colorectal cancer activity.
Qiao S, Li X, Yang S, Hua H, Mao C, Lu W Sci Rep. 2025; 15(1):8238.
PMID: 40065054 PMC: 11893811. DOI: 10.1038/s41598-025-89018-9.
CNPY3's regulation of tumor microenvironment and its impact on colon cancer aggressiveness.
Gao X, Zhou B, Feng X, Ji Z, Li Q, Liu H Mol Med. 2025; 31(1):89.
PMID: 40055606 PMC: 11887163. DOI: 10.1186/s10020-025-01145-1.
Gharaee N, Wegrzyn-Woltosz J, Jiang J, Akhade V, Bridgers J, Stubbins R Leukemia. 2025; .
PMID: 40000845 DOI: 10.1038/s41375-025-02537-2.
Li Z, Deng L, Cheng M, Ye X, Yang N, Fan Z Int J Oncol. 2025; 66(3).
PMID: 39981904 PMC: 11844338. DOI: 10.3892/ijo.2025.5730.